DekaBank Deutsche Girozentrale raised its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 135,569 shares of the medical equipment provider’s stock after buying an additional 1,000 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Zimmer Biomet Holdings were worth $17,446,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. increased its position in Zimmer Biomet Holdings by 4,042.4% in the first quarter. BlackRock Inc. now owns 16,740,383 shares of the medical equipment provider’s stock worth $2,044,168,000 after buying an additional 16,336,262 shares in the last quarter. Vanguard Group Inc. increased its position in Zimmer Biomet Holdings by 3.7% in the first quarter. Vanguard Group Inc. now owns 13,041,411 shares of the medical equipment provider’s stock worth $1,592,488,000 after buying an additional 464,916 shares in the last quarter. State Street Corp increased its position in Zimmer Biomet Holdings by 2.4% in the first quarter. State Street Corp now owns 8,193,165 shares of the medical equipment provider’s stock worth $1,000,463,000 after buying an additional 191,747 shares in the last quarter. Longview Partners Guernsey LTD increased its position in Zimmer Biomet Holdings by 4.4% in the second quarter. Longview Partners Guernsey LTD now owns 6,377,711 shares of the medical equipment provider’s stock worth $818,898,000 after buying an additional 269,184 shares in the last quarter. Finally, Nordea Investment Management AB increased its position in Zimmer Biomet Holdings by 25.0% in the first quarter. Nordea Investment Management AB now owns 4,931,281 shares of the medical equipment provider’s stock worth $602,159,000 after buying an additional 987,398 shares in the last quarter. 83.62% of the stock is owned by hedge funds and other institutional investors.

Shares of Zimmer Biomet Holdings, Inc. (ZBH) opened at 111.70 on Friday. The company has a market capitalization of $22.59 billion, a PE ratio of 31.81 and a beta of 1.20. Zimmer Biomet Holdings, Inc. has a 52 week low of $95.63 and a 52 week high of $133.49. The company’s 50 day moving average is $124.93 and its 200-day moving average is $121.26.

Zimmer Biomet Holdings (NYSE:ZBH) last posted its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $2.08 EPS for the quarter, missing analysts’ consensus estimates of $2.10 by $0.02. The business had revenue of $1.95 billion during the quarter, compared to analyst estimates of $1.95 billion. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. Zimmer Biomet Holdings’s revenue for the quarter was up 1.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.02 EPS. On average, analysts expect that Zimmer Biomet Holdings, Inc. will post $8.24 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Shareholders of record on Friday, September 22nd will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date is Thursday, September 21st. Zimmer Biomet Holdings’s dividend payout ratio is currently 27.59%.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/08/12/zimmer-biomet-holdings-inc-zbh-stake-boosted-by-dekabank-deutsche-girozentrale.html.

ZBH has been the subject of a number of research reports. Canaccord Genuity reaffirmed a “buy” rating on shares of Zimmer Biomet Holdings in a report on Friday, April 28th. Royal Bank Of Canada lifted their price objective on shares of Zimmer Biomet Holdings from $133.00 to $140.00 and gave the stock an “outperform” rating in a report on Wednesday, June 21st. Bank of America Corporation reaffirmed a “buy” rating and issued a $158.00 price objective on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. BidaskClub downgraded shares of Zimmer Biomet Holdings from a “buy” rating to a “hold” rating in a report on Monday, July 24th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $135.00 price objective on shares of Zimmer Biomet Holdings in a report on Friday, July 28th. Four equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $136.90.

In other Zimmer Biomet Holdings news, VP Tony W. Collins sold 16,986 shares of the business’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $121.74, for a total value of $2,067,875.64. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Sang Yi sold 17,731 shares of the business’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $124.56, for a total value of $2,208,573.36. The disclosure for this sale can be found here. 1.07% of the stock is currently owned by insiders.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.